ACCESS Newswire

ITOCO Inc.

27.10.2021 13:56:35 CEST | ACCESS Newswire | Press release

Share
Itoco Provides Information About the Nopal Cactus' Ability To Act as a Key Component in Land Reclamation in Addition to Its Significant Carbon Reducing Properties

TORONTO, ON / ACCESSWIRE / October 27, 2021 / ITOCO INC. (OTC PINK:ITMC) is pleased to release information about the Nopal Cactus' ability to act as a key component to land reclamation in addition to its significant carbon reducing properties.

Desertification or land degradation is occurring worldwide and directly affects millions of people, especially the poor. Nopal Cactus is already widely cultivated in arid regions worldwide as a standalone crop because of its ability to grow and thrive in hard and dry conditions.

Importantly, their root characteristics allow them to prevent or avoid wind and rain erosion. When the Nopal Cactus is present, other plants and trees can take hold in poor growing environments more easily.

ITOCO's Nopal Cactus Carbon Credit program is designed to achieve significant land rehabilitation and reclamation by planting in association with less robust trees and crops. In Mexico, the Nopal Cactus has demonstrated an ability to turn dry desert into savannah like conditions relatively quickly and economically by leveraging it's unique properties.

Therefore, establishment of production systems based on cactus can bring food self-sufficiency in desert and arid areas, and well as reclaiming ‘wasted' land.

The Nopal Cactus is one of the best plants for the reforestation of arid areas as they strongly resist scarce rain and high temperature. Moreover, the Nopal Cactus itself provides food via its leaves and fruit; and can be used as a biofuel, fertilizer, and can be easily processed into an excellent substitute for leather. Cultivation of the Cactus is relatively simple, and the plant grows quickly.

Our ITOCO Nopal Cactus Carbon Capture Program in Mexico has demonstrated Nopal Cactus farming innovations that leverages Nopal Cactus' superb adaptations to dry and arid landscape areas that including fixing carbon dioxide at night and closing the spores (stomata) during the day, thus earning producers carbon credits at an accelerated pace in under twelve months.

ITOCO will be presenting its Nopal Carbon Capture program as an addition to the Great Green Wall project now being implemented in more than 20 countries across Africa. To date, more than eight billion dollars have been mobilized and pledged for its support internationally.

When complete, the Wall will be the largest living structure on the planet - an 8,000 km natural wonder of the world stretching across the entire width of the continent.

We believe that introducing a Nopal Cactus component to the Great Green Wall project would significantly improve the speed and efficacy of the land rehabilitation by allowing other plants to take hold more easily.

The ITOCO Nopal Cactus Program has already been proven with over 1,450 Hectares under management with the support of the Government of Mexico, which has endorsed the Paris Agreement adopted at the twenty-first session of the Conference of the Parties ("COP") to the United Nation Framework Convention on Climate Change ("UNDCC") and is taking action to mitigate its Green House Gas ("GHG') emissions in accordance with the Land Use Protocol of the United Nations (LULUCF), by 2030.

About ITOCO Inc.:

ITOCO's mission is to be a global leader in developing, distributing, and producing Bio Tech related technologies and methodologies in a compliant environmentally friendly manner. ITOCO Inc. trades on the OTC Markets, symbol: ITMC. ITOCO is a 14-year-old publicly quoted specialty Bio Tech development, production and distribution company based in Toronto Canada and Nevada USA. Itoco seeks to partner with outstanding individuals and companies within this field to joint venture, research, and co-develop Bio Tech related products and technologies to the market.

www.itoco.net

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, potential, intends, plans, hopes, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements.

CONTACT:
Michael Paul, C.E.T.
President & CEO
ITOCO INC
ir@itoco.net
+1-800-805-1521
www.itoco.net

SOURCE: ITOCO Inc.



View source version on accesswire.com:
https://www.accesswire.com/669803/Itoco-Provides-Information-About-the-Nopal-Cactus-Ability-To-Act-as-a-Key-Component-in-Land-Reclamation-in-Addition-to-Its-Significant-Carbon-Reducing-Properties

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release

Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica

Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release

OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to

Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release

CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a

Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in

CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets4.2.2026 14:00:00 CET | Press release

TORONTO, ON / ACCESS Newswire / February 4, 2026 / CHAR Technologies Ltd. ("CHAR Tech" or "the Company") (TSXV:YES)(FSE:68K) a leader in sustainable biomass energy solutions, today announced that it has entered into a formal technology know-how licensing agreement with GazoTech SAS ("GazoTech"), a France-based energy developer, to support deployment of CHAR Tech's technology in France and selected European markets. The agreement follows recent commissioning progress at CHAR Tech's Thorold Renewable Energy Facility and complements the Company's ongoing development of larger-scale projects in North America. Under the agreement, CHAR Tech is the licensor of its proprietary High-Temperature Pyrolysis ("HTP") technology, granting GazoTech a know-how licence for projects developed in France as well as certain additional European markets, subject to project-by-project application of the licenced technology. GazoTech has multiple projects in development in France, notably: An industrial integr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye